"Synovial Extracellular Matrix-Specific Chimeric Antigen Receptor For Targeting Regulatory T Cells To Treat Autoimmune Diseases" in Patent Application Approval Process (USPTO 20240010703).
In: Gene Therapy Weekly, 2024-02-02, S. 556-556
serialPeriodical
Zugriff:
A patent application by Sonoma Biotherapeutics Inc. has been made available online for a synovial extracellular matrix-specific chimeric antigen receptor (CAR) that targets regulatory T cells to treat autoimmune diseases. The CAR is engineered to recognize post-translationally modified proteins found in the synovial extracellular matrix of inflamed joints in patients with rheumatoid arthritis (RA). The patent application describes methods for preparing CAR-Treg cells and a pharmaceutical composition containing these cells for the treatment of RA. This research shows promise for a potential new therapy for autoimmune diseases like RA. [Extracted from the article]
Copyright of Gene Therapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
"Synovial Extracellular Matrix-Specific Chimeric Antigen Receptor For Targeting Regulatory T Cells To Treat Autoimmune Diseases" in Patent Application Approval Process (USPTO 20240010703).
|
---|---|
Zeitschrift: | Gene Therapy Weekly, 2024-02-02, S. 556-556 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1078-2842 (print) |
Sonstiges: |
|